miRNA and mRNA Expression Profiles Associated with Lymph Node Metastasis and Prognosis in Penile Carcinoma

Imagem de Miniatura
Arquivos
art_MURTA_miRNA_and_mRNA_Expression_Profiles_Associated_with_Lymph_2022.PDF (1.34 MB)
Citações na Scopus
3
Tipo de produção
article
Data de publicação
2022
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
MDPI
Autores
Citação
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, v.23, n.13, article ID 7103, 13p, 2022
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Penile cancer (PeC) is a rare disease, and no prognostic biomarkers have been adopted in clinical practice yet. The objective of the present study was to identify differentially expressed miRNAs (DEmiRs) and genes (DEGs) as potential biomarkers for lymph node metastasis and other prognostic factors in PeC. Tumor samples were prospectively obtained from 24 patients with squamous cell carcinoma of the penis. miRNA microarray analysis was performed comparing tumors from patients with inguinal lymph node metastatic and localized disease, and the results were validated by qRT-PCR. Eighty-three gene expression levels were also compared between groups through qRT-PCR. Moreover, DEmiRs and DEGs expression levels were correlated with clinicopathological variables, cancer-specific (CSS), and overall survival (OS). TAC software, TM4 MeV 4.9 software, SPSS v.25.0, and R software v.4.0.2 were used for statistical analyses. We identified 21 DEmiRs in microarray analysis, and seven were selected for validation. miR-744-5p and miR-421 were overexpressed in tissue samples of metastatic patients, and high expression of miR-421 was also associated with lower OS. We found seven DEGs (CCND1, EGFR, ENTPD5, HOXA10, IGF1R, MYC, and SNAI2) related to metastatic disease. A significant association was found between increased MMP1 expression and tumor size, grade, pathological T stage, and perineural invasion. Other genes were also associated with clinicopathological variables, CSS and OS. Finally, we found changes in mRNA-miRNA regulation that contribute to understanding the mechanisms involved in tumor progression. Therefore, we identified miRNA and mRNA expression profiles as potential biomarkers associated with lymph node metastasis and prognosis in PeC, in addition to disruption in mRNA-miRNA regulation during disease progression.
Palavras-chave
disease progression, metastasis, microRNA and mRNA expression levels, penile cancer, prognosis, survival analysis, tumor biomarkers
URI
https://observatorio.fm.usp.br/handle/OPI/48358
Referências
  1. Ali SM, 2016, ONCOLOGIST, V21, P33, DOI 10.1634/theoncologist.2015-0241
  2. Andersen CL, 2004, CANCER RES, V64, P5245, DOI 10.1158/0008-5472.CAN-04-0496
  3. Ayoubian H, 2021, CANCERS, V13, DOI 10.3390/cancers13061480
  4. Barzon L, 2014, AM J PATHOL, V184, P3376, DOI 10.1016/j.ajpath.2014.08.004
  5. Benard VB, 2008, CANCER-AM CANCER SOC, V113, P2910, DOI 10.1002/cncr.23742
  6. Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
  7. Cai JJ, 2019, ONCOTARGETS THER, V12, P8437, DOI 10.2147/OTT.S221340
  8. Carthon BC, 2014, BJU INT, V113, P871, DOI 10.1111/bju.12450
  9. Damasdi M, 2017, ANTICANCER RES, V37, P5515, DOI 10.21873/anticanres.11982
  10. Davidsson S, 2019, EUR UROL ONCOL, V2, P214, DOI 10.1016/j.euo.2018.07.010
  11. Deguine Jacques, 2014, F1000Prime Rep, V6, P97, DOI 10.12703/P6-97
  12. Furuya TK, 2021, CANCERS, V13, DOI 10.3390/cancers13194745
  13. Gopman JM, 2015, BJU INT, V116, P196, DOI 10.1111/bju.13009
  14. Hakenberg O.W., EUROPEAN ASS UROLOGY
  15. Hartz JM, 2016, J UROLOGY, V196, P570, DOI 10.1016/j.juro.2016.01.115
  16. Hollander MC, 1999, NAT GENET, V23, P176, DOI 10.1038/13802
  17. Kleter B, 1999, J CLIN MICROBIOL, V37, P2508, DOI 10.1128/JCM.37.8.2508-2517.1999
  18. Kuasne H, 2017, ONCOTARGET, V8, P15294, DOI 10.18632/oncotarget.14783
  19. Li SB, 2022, ANN SURG ONCOL, V29, P1465, DOI 10.1245/s10434-021-10688-6
  20. Li YX, 2018, CANCER MANAG RES, V10, P2627, DOI 10.2147/CMAR.S167432
  21. Liu HY, 2015, INT J CLIN EXP PATHO, V8, P15128
  22. Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
  23. Loh CY, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8101118
  24. McDaniel AS, 2015, CANCER RES, V75, P5219, DOI 10.1158/0008-5472.CAN-15-1004
  25. Miyamae M, 2015, BRIT J CANCER, V113, P1467, DOI 10.1038/bjc.2015.366
  26. Mulherkar R, 2019, BRACHYTHERAPY, V18, P503, DOI 10.1016/j.brachy.2019.04.007
  27. Ornellas AA, 2008, J UROLOGY, V180, P1354, DOI 10.1016/j.juro.2008.06.028
  28. Ornellas AA, 2008, J SURG ONCOL, V97, P487, DOI 10.1002/jso.20980
  29. Pinho Jaqueline Diniz, 2020, Asian Pac J Cancer Prev, V21, P391, DOI 10.31557/APJCP.2020.21.2.391
  30. SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875
  31. Tront JS, 2010, CANCER RES, V70, P9671, DOI 10.1158/0008-5472.CAN-10-2177
  32. Wang C, 2012, INT J CANCER, V130, P2249, DOI 10.1002/ijc.26226
  33. Yang P, 2017, EXP THER MED, V14, P2625, DOI 10.3892/etm.2017.4798
  34. Zhang L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131336

Coleções
Artigos e Materiais de Revistas Científicas - FM/MDR
Artigos e Materiais de Revistas Científicas - FM/MCG
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/24
Artigos e Materiais de Revistas Científicas - LIM/26
Carregar mais